This product is a prescription medicine; ensure you read the leaflet carefully before use.
Mounjaro® 2.5mg – Starting dose to initiate treatment and assess tolerance
Mounjaro 2.5mg is a once-weekly injectable treatment for adults with type 2 diabetes. It contains tirzepatide, a dual GIP and GLP-1 receptor agonist that helps regulate blood sugar and support weight reduction when used alongside diet and exercise.
- Dual-action effect – mimics GIP and GLP-1 hormones to lower glucose and reduce appetite
- Once-weekly injection – delivered by easy-to-use pre-filled pen
- Supports HbA1c reduction – clinically shown to improve long-term glucose control
- Helps with weight loss – as part of a supervised diabetes management programme
Who Is This Product For?
Indicated for adults with type 2 diabetes mellitus when metformin or other medications are insufficient. Also considered in patients with a need to manage weight and reduce cardiovascular risk. Prescribed only under specialist medical supervision.
Active Ingredient
Tirzepatide 2.5mg
How to Use
Inject once per week, on the same day each week. Start with 2.5mg for 4 weeks before increasing to the maintenance or target dose. Follow your clinician’s personalised titration plan. Inject subcutaneously into the abdomen, thigh, or upper arm.
Possible Side Effects
Common effects include nausea, diarrhoea, reduced appetite, or constipation. These typically ease over time. Rare effects include pancreatitis or allergic reaction. If side effects persist or worsen, consult a healthcare professional promptly.
Manufactured to High Standards
Mounjaro® is developed by Eli Lilly and Company and manufactured under rigorous European quality standards. It is authorised for prescription-only use in the UK.
Advisory
Prescription-only medicine. Not suitable for type 1 diabetes or those with a history of pancreatitis. Always follow professional medical advice. Store in the refrigerator. Keep out of reach of children.